Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment
Completed · Phase 1
Conditions studied: Hepatic Impairment
In brief
The main purpose of the study is to evaluate the pharmacokinetics (PK) of a single oral dose of sotorasib administered in participants with moderate or severe hepatic impairment compared to participants with normal hepatic function.
Key facts
- Study ID
- NCT04887064
- Run by
- Amgen
- People needed
- 20
- Starts
- 2021-04-22
- Expected to finish
- 2022-03-09
- Last updated by the study team
- 2024-04-19
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.
Where it is running
- Orange County Research Center — Tustin, California, United States
- Clinical Pharmacology Of Miami LLC — Miami, Florida, United States
- Orlando Clinical Research Center — Orlando, Florida, United States
- American Research Corporation — San Antonio, Texas, United States
- Pinnacle Clinical Research - San Antonio — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.